Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 7Colorectal Neoplasms 7Colonic Neoplasms 3Rectal Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Nasopharyngeal Carcinoma 1Lung Neoplasms 1Klatskin Tumor 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Epstein-Barr Virus Infections 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Cisplatin 31Fluorouracil 24Paclitaxel 19Radiotherapy 15Docetaxel 11Esophagectomy 8Radiation 7Neoadjuvant Therapy 7Carboplatin 7Irinotecan 6Oxaliplatin 5Leucovorin 5Capecitabine 5sintilimab 4pembrolizumab 4camrelizumab 4TP protocol 4Surgical Procedures, Operative 4Drug Therapy 4Chemotherapy, Adjuvant 4Trastuzumab 3Immunotherapy 3Epirubicin 3Chemoradiotherapy 3tislelizumab 2nimotuzumab 2S 1 (combination) 2Radiotherapy, Adjuvant 2Platinum Compounds 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Esophageal Neoplasms × Tegafur × Clear all
NCT04415853 2025-05-18

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Sunshine Lake Pharma Co., Ltd.

Phase 3 Recruiting
416 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡